From Lab to Market: The Financing Gap Plaguing the Deeptech Sector

Why It Matters

The financing shortfall threatens India’s ability to commercialise world‑class deep‑tech, potentially diverting economic value and strategic capability to foreign ecosystems.

Key Takeaways

• India deeptech raised $1.65 billion in 2025, up from prior years
• Series A and later rounds remain scarce for capital‑intensive deeptech firms
• Venture capital models prioritize fast‑scaling software over hardware‑heavy deeptech
• Founders often dilute equity or shift abroad to secure needed funding
• Private investors must provide patient capital to bridge the valley of death

Pulse Analysis

India’s deep‑tech boom is reshaping sectors from semiconductors to quantum computing, but the financing pipeline is uneven. While early‑stage capital surged to $1.65 billion in 2025, the transition from prototype to production remains starved of growth‑stage money. This mismatch creates a classic "valley of death" where high‑cost, long‑run projects need patient funding that traditional venture capital, built for rapid‑scale software, simply does not provide. As a result, many promising ventures either stall or scramble for alternative sources.

Globally, deep‑tech investors face similar hurdles, yet ecosystems like the United States benefit from larger pools of institutional capital willing to back capital‑intensive rounds. In Europe, dedicated deep‑tech funds have emerged, but they still lag behind U.S. growth‑stage financing. India’s comparatively thin growth‑stage market amplifies the problem, leaving founders to either over‑dilute equity or relocate operations abroad. The consequence is not just financial strain; it risks shifting intellectual property and talent out of the country, eroding the strategic advantage that home‑grown deep‑tech could deliver.

Policy initiatives—such as dedicated deep‑tech funds and procurement incentives—signal governmental support, yet they cannot substitute for deep‑pocketed private investors. Institutional players, pension funds, insurance firms and family offices must recognize deep‑tech as a long‑term, high‑impact asset class and allocate patient capital accordingly. Bridging the financing gap will enable Indian innovators to scale domestically, retain IP, and cement the nation’s role in the next wave of technological leadership. The sector’s technical readiness is evident; the missing piece is a robust, patient capital ecosystem.